These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract. Cai YJ; Ke LF; Zhang WW; Lu JP; Chen YP BMC Cancer; 2021 Jun; 21(1):677. PubMed ID: 34102999 [TBL] [Abstract][Full Text] [Related]
6. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667 [TBL] [Abstract][Full Text] [Related]
7. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas. Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760 [TBL] [Abstract][Full Text] [Related]
8. Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature. Chłopek M; Lasota J; Thompson LDR; Szczepaniak M; Kuźniacka A; Hińcza K; Kubicka K; Kaczorowski M; Newford M; Liu Y; Agaimy A; Biernat W; Durzyńska M; Dziuba I; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kato H; Kopczyński J; Michal M; Michal M; Pęksa R; Prochorec-Sobieszek M; Starzyńska A; Takahashi S; Wasąg B; Kowalik A; Miettinen M Mod Pathol; 2022 Nov; 35(11):1609-1617. PubMed ID: 35978013 [TBL] [Abstract][Full Text] [Related]
9. Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667 [No Abstract] [Full Text] [Related]
10. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy. Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010 [TBL] [Abstract][Full Text] [Related]
12. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets. Lyu J; Song Z; Chen J; Shepard MJ; Song H; Ren G; Li Z; Guo W; Zhuang Z; Shi Y J Pathol; 2018 Mar; 244(3):358-366. PubMed ID: 29230811 [TBL] [Abstract][Full Text] [Related]
13. The mutational landscape of mucosal melanoma. Nassar KW; Tan AC Semin Cancer Biol; 2020 Apr; 61():139-148. PubMed ID: 31655118 [TBL] [Abstract][Full Text] [Related]
14. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240 [TBL] [Abstract][Full Text] [Related]
15. Identification of recurrent mutational events in anorectal melanoma. Yang HM; Hsiao SJ; Schaeffer DF; Lai C; Remotti HE; Horst D; Mansukhani MM; Horst BA Mod Pathol; 2017 Feb; 30(2):286-296. PubMed ID: 27739435 [TBL] [Abstract][Full Text] [Related]